DK0720482T3 - Prosaposin og cytokin-afledte peptider som terapeutiske midler - Google Patents

Prosaposin og cytokin-afledte peptider som terapeutiske midler

Info

Publication number
DK0720482T3
DK0720482T3 DK94925117T DK94925117T DK0720482T3 DK 0720482 T3 DK0720482 T3 DK 0720482T3 DK 94925117 T DK94925117 T DK 94925117T DK 94925117 T DK94925117 T DK 94925117T DK 0720482 T3 DK0720482 T3 DK 0720482T3
Authority
DK
Denmark
Prior art keywords
prosaposin
cytokine
derived peptides
promote
therapeutic agents
Prior art date
Application number
DK94925117T
Other languages
Danish (da)
English (en)
Inventor
John S O'brien
Yasuo Kishimoto
Original Assignee
Univ California
Myelos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/100,247 external-priority patent/US5571787A/en
Application filed by Univ California, Myelos Corp filed Critical Univ California
Application granted granted Critical
Publication of DK0720482T3 publication Critical patent/DK0720482T3/da

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E03—WATER SUPPLY; SEWERAGE
    • E03B—INSTALLATIONS OR METHODS FOR OBTAINING, COLLECTING, OR DISTRIBUTING WATER
    • E03B7/00—Water main or service pipe systems
    • E03B7/07—Arrangement of devices, e.g. filters, flow controls, measuring devices, siphons or valves, in the pipe systems
    • E03B7/074—Arrangement of water treatment devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Water Supply & Treatment (AREA)
  • Hydrology & Water Resources (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK94925117T 1993-07-30 1994-07-28 Prosaposin og cytokin-afledte peptider som terapeutiske midler DK0720482T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/100,247 US5571787A (en) 1993-07-30 1993-07-30 Prosaposin as a neurotrophic factor
US08/232,513 US5700909A (en) 1993-07-30 1994-04-21 Prosaposin and cytokine-derived peptides
PCT/US1994/008453 WO1995003821A1 (fr) 1993-07-30 1994-07-28 Prosaposine et peptides derives de la cytokine utilises comme agents therapeutiques

Publications (1)

Publication Number Publication Date
DK0720482T3 true DK0720482T3 (da) 2004-06-21

Family

ID=26796947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94925117T DK0720482T3 (da) 1993-07-30 1994-07-28 Prosaposin og cytokin-afledte peptider som terapeutiske midler

Country Status (11)

Country Link
US (1) US5700909A (fr)
EP (1) EP0720482B1 (fr)
JP (2) JP4070803B2 (fr)
AT (1) ATE259828T1 (fr)
AU (1) AU7515494A (fr)
CA (1) CA2168029C (fr)
DE (1) DE69433562T2 (fr)
DK (1) DK0720482T3 (fr)
ES (1) ES2215999T3 (fr)
PT (1) PT720482E (fr)
WO (1) WO1995003821A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5910568A (en) * 1996-01-11 1999-06-08 The Penn State Research Foundation Molecule involved in binding of sperm to egg surfaces and procedures for use of this molecule to enhance or decrease potential fertility
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
AU4267297A (en) * 1997-09-11 1998-09-22 Regents Of The University Of California, The Method of alleviating neuropathic pain
EP0979238A4 (fr) * 1997-03-05 2000-08-23 Univ California Procedes pour soulager les douleurs neuropathiques
EP0971956A2 (fr) * 1997-03-24 2000-01-19 Myelos Corporation Peptides neurotrophiques de synthese derives de la saposine c
EP0996856A1 (fr) * 1997-07-17 2000-05-03 Myelos Corporation Bioanalyse du recepteur de la prosaposine
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides
CA2304108A1 (fr) * 1997-09-09 1999-03-18 The Regents Of The University Of California Inhibition de l'apoptose au moyen d'agonistes du recepteur de la prosaposine
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
JP2002509081A (ja) * 1998-03-12 2002-03-26 バイオポア アイエヌシー． 精子−卵結合に関与する分子の受精前の作用の増強
WO2000002902A1 (fr) * 1998-07-13 2000-01-20 Gill Parkash S Nouveaux inhibiteurs de l'angiogenese et de la croissance tumorale
JP2002524025A (ja) * 1998-07-23 2002-08-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経栄養因子のプロサポシンファミリーと相同性を有するヒトｓｂｐｓａｐｌ遺伝子
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
HUP0103994A3 (en) * 1998-09-09 2004-03-01 Myelos Corp San Diego Method of stimulating prosaposin receptor activity
US20020028783A1 (en) * 1999-09-09 2002-03-07 O'brien John S. Method of stimulating prosaposin receptor activity
CN1324251A (zh) * 1998-09-09 2001-11-28 迈洛斯公司 刺激前塞波素受体活性的方法
AU4328500A (en) * 1999-03-30 2000-10-16 Myelos Corporation Retro-inverso prosaposin-derived peptides and use thereof
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7115571B1 (en) * 2000-06-16 2006-10-03 Myelos Corporation Retro-inverso peptides derived from interleukin-3
US7135461B1 (en) * 2000-06-16 2006-11-14 Myelos Corporation Retro-inverso peptides derived from interleukin-6
IL147095A0 (en) * 1999-06-16 2002-08-14 Myelos Corp Retro-inverso peptides derived from leukemia inhibitory factor
CA2376394A1 (fr) * 1999-06-16 2000-12-21 David E. Wright Peptides retro-inverso derives de l'interleukine-3
JP4786843B2 (ja) * 1999-06-16 2011-10-05 マイアロス コーポレイション インターロイキン−６から誘導されるレトロ−インベルソペプチド
US7109168B1 (en) * 2000-06-16 2006-09-19 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
JP2001010972A (ja) * 1999-06-30 2001-01-16 Masahiro Sakanaka プロサポシン関連ペプチドからなる細胞保護剤
AU1472701A (en) * 1999-11-12 2001-06-06 Human Genome Sciences, Inc. 28 human secreted proteins
WO2001055198A2 (fr) * 2000-01-26 2001-08-02 Memorec Medical Molecular Research Cologne Stoffel Gmbh Activateur de sphingolipide specifique de la peau et de l'estomac
US6872406B2 (en) * 2000-02-11 2005-03-29 Children's Hospital Research Foundation Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
WO2002002135A1 (fr) * 2000-06-30 2002-01-10 Tokyo Metropolitan Institute Of Gerontology Preventifs et remedes contre des maladies associees a la demyelinisation
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
NZ548578A (en) * 2001-02-02 2008-03-28 Ortho Mcneil Pharm Inc Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US20060287240A1 (en) * 2001-03-09 2006-12-21 O'brien John S Method of stimulating prosaposin receptor activity
US20040122216A1 (en) * 2002-07-01 2004-06-24 Jacob Nielsen Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
MXPA06003234A (es) * 2003-09-29 2006-06-08 Warren Pharmaceuticals Inc Citosinas protectoras de los tejidos para el tratamiento y prevencion de la sepsis y la formacion de adhesiones.
US20050260258A1 (en) 2003-12-18 2005-11-24 The Texas A&M University System Use of vitelline protein B as a microencapsulating additive
EP2377884A1 (fr) 2005-05-10 2011-10-19 Neoloch Aps Peptides neuritogènes
KR20170027868A (ko) 2005-08-05 2017-03-10 아라임 파마슈티칼즈, 인크. 조직 보호 펩티드 및 이의 용도
WO2007112566A1 (fr) * 2006-03-31 2007-10-11 Queen's University At Kingston Compositions et procédés de traitement de l'athérosclérose
CA2692171C (fr) 2007-06-22 2019-10-22 Randolph Watnick Procedes et utilisations de prosaposine
AU2013203640B2 (en) * 2007-06-22 2017-04-13 Children's Medical Center Corporation Methods and uses thereof of prosaposin
WO2011084685A2 (fr) 2009-12-17 2011-07-14 Children's Medical Center Corporation Peptides dérivés de saposine a et utilisations de ceux-ci
NZ587105A (en) 2008-01-22 2012-09-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US10736935B2 (en) 2011-12-22 2020-08-11 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
EP2971166B1 (fr) 2013-03-14 2021-05-19 Children's Medical Center Corporation Peptide psap pour traiter les cancers exprimant cd36
CN106030302B (zh) * 2013-12-12 2019-09-24 布里格姆妇女医院 治疗神经变性疾病
EP3122369B1 (fr) 2014-03-26 2022-08-31 Children's Medical Center Corporation Peptides de prosaposine cycliques et utilisations de ceux-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709400D0 (en) * 1987-04-21 1987-05-28 Smith A D Acetylcholinesterase
CA2019714A1 (fr) * 1989-06-27 1990-12-27 Richard A. Chizzonite Procede de dosage des interleukines
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０

Also Published As

Publication number Publication date
JPH09503999A (ja) 1997-04-22
CA2168029C (fr) 2009-07-07
EP0720482A1 (fr) 1996-07-10
CA2168029A1 (fr) 1995-02-09
DE69433562D1 (de) 2004-03-25
JP2007314575A (ja) 2007-12-06
US5700909A (en) 1997-12-23
EP0720482A4 (fr) 1997-11-26
ES2215999T3 (es) 2004-10-16
AU7515494A (en) 1995-02-28
WO1995003821A1 (fr) 1995-02-09
EP0720482B1 (fr) 2004-02-18
DE69433562T2 (de) 2004-12-16
ATE259828T1 (de) 2004-03-15
PT720482E (pt) 2004-07-30
JP4070803B2 (ja) 2008-04-02

Similar Documents

Publication Publication Date Title
DK0720482T3 (da) Prosaposin og cytokin-afledte peptider som terapeutiske midler
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
ES2140082T3 (es) Composiciones peptidicas con actividad de tipo factor de crecimiento.
HUP0004234A2 (hu) Dolasztatin-15-származékok
GR3034533T3 (en) Fused pyrrolo(2,3-c)carbazole-6-ones which potentiate activity of gamma interferon
FR2662698B1 (fr)
MY104909A (en) Peptide compounds.
EP1074264A4 (fr) Inhibiteurs de neovascularisation
DK0842193T3 (da) Somatostatin-analoge cykliske peptider med hæmmende aktivitet på væksthormon
IL110585A0 (en) Tripeptides, their preparation and pharmaceutical compositions containing them
DK0925064T3 (da) 5-Androsten-3-beta,17-alpha-diol som inhibitor for tumorvækst
ATE174927T1 (de) Haemoregulatorische penta-oder hexapeptide
NO910981L (no) Peptidforbindelser.